This Article Full Text Full Text (PDF) All Versions of this Article: 40/3_suppl_1/S64    most recent STROKEAHA.108.533190v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation Related Collections Other Stroke Treatment - Medical

(Stroke. 2009;40:S64.)
© 2009 American Heart Association, Inc.

Prevention 1: Genetics

Exploiting Common Genetic Variation to Make Anticoagulation Safer

From the Center for Human Genetic Research and Department of Neurology, Massachusetts General Hospital, Boston, Mass; and the Program in Medical and Population Genetics, Broad Institute, Cambridge, Mass.

Correspondence to Jonathan Rosand, MD, MSc, Center for Human Genetic Research, Massachusetts General Hospital, 185 Cambridge Street, CPZN 6818, Boston, MA 02114. E-mail jrosand@partners.org

Key Words: anticoagulation

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
Within the past 2 years, genomewide association studies have identified nearly 200 new chromosomal regions at which variation in DNA sequence influences risk of common human diseases as well as traits such as height and eye color. The success of the genomewide association study method, particularly given the limited success of previous approaches to find these "culprit" loci, has heightened optimism for the development of so-called personalized medicine. Perhaps more than any area, the field of anticoagulation and making it safer has raised hopes for using genetic information to improve individual patient outcomes.

Discoveries, before the genomewide association study era, that common DNA sequence variants in CYP2C9 and VKORC1 play a substantial role in determining an individual’s warfarin dose requirement, led to an update of the US Food and Drug Administration label for Coumadin/warfarin suggesting that clinicians consider genetic testing before initiating warfarin.¹ Although these discoveries represent a crucial first step toward the application of genetic information to make anticoagulation safer, it is clear that identifying an individual patient’s risk for hemorrhage on anticoagulation or thromboembolism in atrial fibrillation (and other diseases) will require many more genetic discoveries.

	What Causes Hemorrhage in Patients Receiving Anticoagulation?

 
Broadly speaking, the risk of bleeding on anticoagulation can be broken down into 2 general mechanisms: those related to the effects of anticoagulation itself on coagulation factors and clot formation and those related to specific conditions that increase risk of bleeding regardless of whether anticoagulation is present. Warfarin metabolism and sensitivity genes such as CYP2C9 and VKORC1 are likely to increase bleeding . . . [Full Text of this Article]